research Persistently Curly Hair Phenotype With the Use of Nivolumab for Squamous Cell Lung Cancer
A cancer patient's hair became permanently curly after treatment with nivolumab.
Search
for
Sort by
Research
30 / 60 resultsresearch Nivolumab-Induced Alopecia Areata: A Case Report and Literature Review
Nivolumab can cause hair loss as a rare side effect.
research Resolution of Paraneoplastic Alopecia Areata Following Nivolumab in a Patient With Metastatic Melanoma
Nivolumab treatment led to hair regrowth in a man with metastatic melanoma and alopecia areata.
research Perifollicular Pink Halo: A Potential Dermoscopic Marker of Inflammation in Central Centrifugal Cicatricial Alopecia
Certain immune markers may predict chemotherapy response in mesothelioma, and nivolumab is a tolerable and effective treatment for advanced non-small cell lung cancer.
research Panhypopituitarism Induced by CTLA-4 and PD-1/PD-L1 Inhibitor Immunotherapy
Immunotherapy for cancer caused a patient to develop a condition affecting hormone production, requiring ongoing hormone replacement therapy.
research Decreased Benzothiazole-Type Pheomelanin in Regrown Brown Hair in Alopecia Areata
The girl's regrown brown hair had less of certain pigments than her original black hair.
research Multiple Sclerosis and Alopecia Areata: Drug-Induced Alopecia Areata or Coexisting Autoimmune Phenomena?
Some multiple sclerosis treatments may trigger hair loss conditions like alopecia areata.
research Cutaneous Toxicities of New Treatments for Melanoma
New melanoma treatments can cause skin side effects, including skin cancer and rashes, but combining treatments may reduce these risks.
research Cutaneous Manifestations Associated With Immune Checkpoint Inhibitors
Immune checkpoint inhibitors can cause skin issues but are linked to better cancer outcomes.
research Ongoing Concerns Regarding Finasteride for the Treatment of Male-Pattern Androgenetic Alopecia
Finasteride may cause side effects; more research needed.
research Perspectives in Head and Neck Medical Oncology
The document concludes that systemic therapy is becoming more important in treating head and neck cancer, with new treatments showing promise.
research Alopecia Areata and Homeopathy
The document says homoeopathic treatments are good for hair regrowth in alopecia areata but doesn't give proof.
research Toxic Side Effects of Targeted Therapies and Immunotherapies Affecting the Skin, Oral Mucosa, Hair, and Nails
Cancer treatments targeting specific cells and the immune system can cause skin, mouth, hair, and nail problems, affecting patients' quality of life and treatment adherence.
research Alopecia Areata: A Multifactorial Autoimmune Condition
Alopecia areata is an autoimmune disease causing patchy hair loss, often with other autoimmune disorders, but its exact causes are unknown.
research Tregs: Where We Are and What Comes Next?
The conclusion is that Treg-targeted therapies have potential, but more knowledge of Treg biology is needed for effective treatments, including for cancer.
research Immune-Related Alopecia (Areata and Universalis) in Cancer Patients Receiving Immune Checkpoint Inhibitors
Cancer patients treated with immune checkpoint inhibitors may develop alopecia, but some hair regrowth is possible with treatment.
research Human αβ and γδ T Cells in Skin Immunity and Disease
Certain types of T cells are essential for healthy skin and play a role in skin diseases, but more research is needed to improve treatments.
research Hair Disorders in Patients with Cancer
Cancer treatments often cause hair disorders, significantly affecting patients' quality of life, and better management methods are needed.
research Autoimmunity and Autoimmune Co-Morbidities in Psoriasis
Psoriasis is linked to other autoimmune diseases and involves a specific inflammatory process.
research Drug Repurposing: Hypothesis, Molecular Aspects, and Therapeutic Applications
research Clinical Management of Cutaneous Adverse Events in Patients on Targeted Anticancer Therapies and Immunotherapies: A National Consensus Statement by the Spanish Academy of Dermatology and Venereology and the Spanish Society of Medical Oncology
Spanish experts provided guidelines for treating skin side effects in cancer patients on new therapies, stressing early action and teamwork.
research Alopecia in Association with Malignancy: A Review
Hair loss in cancer patients can be related to the cancer itself, treatment, or other conditions, and understanding it is important for diagnosis and patient care.
research A Comparative Analysis of Immune Privilege in Pregnancy and Cancer in the Context of Checkpoint Blockade Immunotherapy
The document concludes that pregnancy and cancer share immune evasion tactics, but more research is needed before using checkpoint blockade immunotherapy in pregnant cancer patients to avoid harm to the placenta.
research Hair Matters in Melanoma Biology
The document concludes that the immune-inhibitory environment of the hair follicle may prevent melanoma development.
research Reversing Gray Hair: Inspiring the Development of New Therapies Through Research on Hair Pigmentation and Repigmentation Progress
Gray hair can potentially be reversed, leading to new treatments.
research Scalp Hair Repigmentation in the Penumbral Region of Radiotherapy: A Case Series
Radiotherapy can cause rare changes in hair color, which should be discussed with patients.
research Dermatologic Adverse Events from Cancer Treatments
Cancer treatments can cause skin-related side effects that may affect patient quality of life and require changes in treatment.
research Management of Toxicities of Targeted Therapies
Targeted therapies for lung cancer are effective but require careful management of side effects to benefit patients.
research NF-κB in Biology and Targeted Therapy: New Insights and Translational Implications
NF-κB signaling is crucial in many diseases and can be targeted for new treatments.
research Leflunomide: An Unlikely Trigger and Mechanistically a Beneficial Drug for Alopecia Areata
Leflunomide is more likely to help treat alopecia areata than cause it.